Poster zum Thema "COVID-19"

Zurück
  • PS-3-1
Immunoadsorption as a method of antibody donation during the Covid-19 pandemic
  • PS-3-10
A randomised open-label trial of early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 as model of early treatment in a pandemia with a new pathogen: Experience from collection of very high-titer plasma from superimmunized individuals
  • PS-3-11
Effective neutralizing and cellular immunity against SARS-CoV-2 after mRNA booster vaccination is associated with the activation of B cells and pDCs
  • PS-3-12
SARS-CoV-2 immunity in blood donors during the Omicron BA.5 infection wave – the COVIMBA-study
  • PS-3-2
Reactivation of Epstein-Barr-Virus is not causative for post-COVID-19-syndrome
  • PS-3-3
SARS-CoV2 mRNA vaccine-specific B-, T-, humoral responses in pediatric stem cell transplant recipients – Importance of a booster vaccination
  • PS-3-4
Validation of a modified rapid antibody test to identify COVID-19 patients with low neutralizing antibody titers in an outpatient setting
  • PS-3-5
Is immunoapheresis a therapeutic option for post-COVID patients? Data presentation in the treatment of ME/CFS, Post Covid, Post Vaccine (Long Covid syndrome) with immunoadsorption
  • PS-3-6
Prevalence of wildtype and vaccination induced SARS-CoV2 antibodies in a blood donor population
  • PS-3-7
Immune adsorption as an individual experimental therapy in two patients with multiple autoantibodies and post-COVID-19 syndrome
  • PS-3-8
Autoantibodies against G-protein-coupled receptors can be detected in post/long-COVID-19 patients with fatigue syndrome (ME/CFS) as well as in healthy blood donors
  • PS-3-9
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays